Search
Ofatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigationalIt is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. … Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells.
Products: Jemvy 20 mg/0,4 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 ADET, JEMVY 20 MG/0,4 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.
Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS® 10 MG /ML SOLUCION INYECTABLEMethylergometrine
go.drugbank.com/drugs/DB00353ApprovedInvestigationalA homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: 9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamide, D-lysergic acid 1-butanolamideStanozolol
go.drugbank.com/drugs/DB06718ApprovedVet approvedStanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema.
Products: อโซลอล 5 มก.Atezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. … [L7489] Atezolizumab was granted FDA approval on 18 October 2016.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: TECENTRIQ 1200 MG / 20 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, TECENTRIQ CONCENTRATE FOR SOLUTION FOR INFUSION 1200 MG/ 20 MLAsfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.
Products: STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETTestosterone enanthate
go.drugbank.com/drugs/DB13944ApprovedInvestigationalTestosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate. … s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659].
Mixtures: NOFERTYL® INYECTABLECategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesDual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
go.drugbank.com/bio_entities/BE0003323TargetHumansCyclic nucleotide phosphodiesterase with a dual specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes (PubMed:15260978, PubMed:8855339, PubMed:9419816). Has a preference f...
Polypeptides: Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BFunction: 3',5'-cyclic-AMP phosphodiesterase activityRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma
go.drugbank.com/bio_entities/BE0003557TargetHumansInhibitory gamma subunit of the cone-specific cGMP phosphodiesterase (PDE6) complex which hydrolyzes 3',5'-cyclic GMP in the phototransduction cascade (By similarity).
Polypeptides: Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaFunction: 3',5'-cyclic-GMP phosphodiesterase activityPiroxicam
go.drugbank.com/drugs/DB00554ApprovedInvestigationalA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea
Categories: Cytochrome P-450 Substrates, Non COX-2 selective NSAIDSSynonyms: 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid